NNVC — NanoViricides Share News
0.000.00%
Last trade - 00:00Explainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments
Brief: Nanoviricides Investigating Possibility Of Using NV-387 For Treatment Of Mpox
Brief: Nanoviricides Plans On Exploring Effectiveness Of NV-387 For Treatment Of Severe Acute Respiratory Infections Caused By Viruses
Brief: NanoViricides Says NV-387 Effective In Protecting Lungs From Damage In Lethally Infected Animal Model
Brief: Nanoviricides Ultra-Broad Antiviral Activity Spectrum Of NV-387 Includes Activity Against Orthopoxvirus Family (Smallpox/Mpox)
Brief: Nanoviricides Files Prospectus Supplement Related To Issuance, Sale Of Up To $5.7 Mln Common Stock
RCS - NanoViricides, Inc. - NanoViricides: Clinical Trials, Antiviral NV-CoV-2
Brief: Nanoviricides Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Brief: Nanoviricides Inc - On March 27, Co Entered Into License Agreement With Karveer Meditech Private Limited
U.S. STOCKS ON THE MOVE-Global Blood, Alibaba.com, Albemarle
NanoViricides pulls back after prior session surge
AMEX RESUMED NANOVIRICIDES
AMEX HALT ADDITIONAL INFORMATION LAST 6.890000
AMEX RESUMED NANOVIRICIDES
AMEX HALT ADDITIONAL INFORMATION LAST 5.450000